Menu

Blog

Archive for the ‘biotech/medical’ category: Page 1449

Jul 8, 2020

RNA key in helping stem cells know what to become

Posted by in categories: biotech/medical, genetics, neuroscience

Look deep inside our cells, and you’ll find that each has an identical genome –a complete set of genes that provides the instructions for our cells’ form and function.

But if each blueprint is identical, why does an eye cell look and act differently than a skin cell or brain cell? How does a stem cell—the raw material with which our organ and tissue cells are made—know what to become?

In a study published July 8, University of Colorado Boulder researchers come one step closer to answering that fundamental question, concluding that the molecular messenger RNA (ribonucleic acid) plays an indispensable role in cell differentiation, serving as a bridge between our genes and the so-called “epigenetic” machinery that turns them on and off.

Jul 8, 2020

Examining trapped ion technology for next generation quantum computers

Posted by in categories: biotech/medical, cybercrime/malcode, internet, quantum physics

:3333


Quantum computers (QC) are poised to drive important advances in several domains, including medicine, material science and internet security. While current QC systems are small, several industry and academic efforts are underway to build large systems with many hundred qubits.

Towards this, computer scientists at Princeton University and physicists from Duke University collaborated to develop methods to design the next generation of quantum computers. Their study focused on QC systems built using trapped ion (TI) technology, which is one of the current front-running QC hardware technologies. By bringing together computer architecture techniques and device simulations, the team showed that co-designing near-term hardware with applications can potentially improve the reliability of TI systems by up to four orders of magnitude.

Continue reading “Examining trapped ion technology for next generation quantum computers” »

Jul 8, 2020

State Reports No COVID-19 Deaths Since Yesterday; ‘First Time In Months:’ Governor

Posted by in category: biotech/medical

COVID-19 hospitalizations in Connecticut increased by 14 since Monday, but the state is reporting no new coronavirus-related deaths for the “first time in months,” Governor Ned Lamont announced at a press conference Tuesday afternoon.

“I’m paid to worry,” the governor said when talking about the hospitalizations increasing. “I would worry if I saw our admissions in our hospitals going up and that’s why you saw hospitalizations going up. That’s not what happened. We’ve added between about 20 and 30 new COVID cases a day into our hospitals. That’s consistent. That’s been consistent for the last few weeks. What is happened is there are many fewer discharges. It’s not something I worry about, just something I note to you.”

According to the state Department of Health, 5,745 tests have been administered since yesterday, and just 57 new cases were reported. Lamont said the state’s positive test percentage remains around one percent.

Jul 8, 2020

This Company Wants to Rewrite the Future of Genetic Disease

Posted by in categories: biotech/medical, genetics

Tessera Therapeutics is developing a new class of gene editors capable of precisely plugging in long stretches of DNA—something that Crispr can’t do.

Jul 7, 2020

An intriguing—but far from proven—HIV cure in the ‘São Paulo Patient’

Posted by in category: biotech/medical

A 36-year-old man in Brazil has seemingly cleared an HIV infection—making him the proof of principle in humans of a novel drug strategy designed to flush the AIDS virus out of all of its reservoirs in the body. But scientists caution that the success hasn’t been long or definitive enough to label it a cure…so granted it worked, not so fast.


Vitamin and antiviral drugs appear to clear AIDS virus, but it could still be hiding out in tissue reservoirs.

Jul 7, 2020

First studies from largest-ever human genome database released

Posted by in categories: biotech/medical, genetics

The Genome Aggregation Database has collected 15,708 genomes and 125,748 exomes (the protein-coding part of the genome) to help shed light on how genetic mutations can lead to disease. Dr Daniel MacArthur, scientific lead of the gnomAD Project, explains how the project started, how they collect the data and what they hope to achieve.

Jul 7, 2020

High Blood Pressure May Lead to Low Brain Volume

Posted by in categories: biotech/medical, neuroscience

Having hypertension in midlife (ages 40 through 60) is associated with elevated risk of cognitive impairment and Alzheimer’s dementia later in life, even more so than having the so-called Alzheimer’s gene.

“It is clear that cerebral vascular disease”—that is, hardening of the arteries inside our brain—“and cognitive decline travel hand in hand,” something I’ve addressed before. “However, the independent association of AD [Alzheimer’s disease] with multiple AVD [atherosclerotic vascular disease] risk factors suggests that cholesterol is not the sole culprit in dementia.”

As I discuss in my video Higher Blood Pressure May Lead to Brain Shrinkage, one of the most consistent findings is that elevated levels of blood pressure in midlife, ages 40 through 60, is associated with elevated risk of cognitive impairment and Alzheimer’s dementia later in life—in fact, even more so than having the so-called Alzheimer’s gene.

Jul 7, 2020

More Humanin Increases Chances for Healthier Living to 100

Posted by in categories: biotech/medical, life extension

Aging/longevity/heathspan fans!!


Higher levels of humanin, a peptide encoded in the small genome of the mitochondria, in the body is linked to longer lifespans and better health.

Aging Journal – The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan

Continue reading “More Humanin Increases Chances for Healthier Living to 100” »

Jul 7, 2020

Fighting Antibody Cocktail Being Tested in Thousands of People

Posted by in category: biotech/medical

An antibody cocktail designed to prevent and treat COVID-19 is now entering late-stage clinical trials, according to reports.

When naturally infected with COVID-19, the body generates Y-shaped molecules called antibodies that latch onto the virus and mark it for destruction, or hinder its ability to infect healthy cells, Live Science previously reported. These antibodies can be drawn from recovered COVID-19 patients and injected into sick patients to bolster their immune systems against the virus, a treatment known as convalescent plasma therapy.

Jul 7, 2020

Novavax Secures $1.6 Billion from U.S. Government for COVID-19 Vaccine Program

Posted by in categories: biotech/medical, government, health

Gaithersburg, Md.-based Novavax said the funding will allow the company to participate in Operation Warp Speed, the government’s program that has a goal of supporting the development of hundreds of millions of vaccine doses by 2021. The funding granted to Novavax will support the late-stage clinical development of the vaccine candidate, including a pivotal Phase III study. Additionally, the funds will be used to establish large-scale manufacturing in order to deliver 100 million doses of NVX‑CoV2373 by the end of the year.

Stanley C. Erck, president and chief executive officer of Novavax, said the company was honored to partner with Operation Warp Speed, a program that is supporting multiple shots on goal against COVID-19 by backing multiple vaccine projects, including Moderna’s mRNA program and AstraZeneca’s vaccine candidate.

“The pandemic has caused an unprecedented public health crisis, making it more important than ever that industry, government and funding entities join forces to defeat the novel coronavirus together. We are grateful to the U.S. government for its confidence in our technology platform, and are working tirelessly to develop and produce a vaccine for this global health crisis,” Erck said in a statement.